Dyne Therapeutics, Inc.
NASDAQ:DYNBiotechnology
+$0.38 today
- Market cap
- $2.97B
- Beta
- 1.08
- P/E (TTM)
- -7.2
- EPS (TTM)
- -$2.74
Volume 2.93M
Average 1.71M
DYN Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Dyne Therapeutics, Inc.NASDAQ: DYN
Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026
Cash & equivalents rises 39.4% from a year ago
Cash & equivalents stood at $676.11M at the end of Q2 FY2026, up 39.4% from a year earlier and down 10.2% from the prior quarter. Over 3 fiscal years it compounded at +73.1% a year.
Context
- Cash & equivalents amounted to 68.0% of total assets at the end of Q2 FY2026, up 1.5 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +39.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 893.37M USD
- Year-over-year change
- +105.2%
- 4-year CAGR
- +45.2%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 893.37M | +105.2% |
| FY2024 | 2024-12-31 | 435.45M | +258.0% |
| FY2023 | 2023-12-31 | 121.63M | -29.3% |
| FY2022 | 2022-12-31 | 172.15M | -14.3% |
| FY2021 | 2021-12-31 | 200.83M | — |
Cash & Equivalents vs competitors
How DYN compares with its peers on the latest reported figures
- DYN's Jun 2026 cash & equivalents of $676.11M is the 2nd highest of the 11 companies compared; the peer median is $237.11M.
- Its year-over-year change of +39.4% is the 6th highest of 11, against a peer median of +27.0%.
- Cash & equivalents amounts to 68.0% of total assets for DYN, versus a peer median of 32.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $1.05B | +3.2% | +52.1% | 32.3% | |
| Jun 2026 | $676.11M | +39.4% | +73.1% | 68.0% | |
| Mar 2026 | $544.59M | +124.0% | +89.5% | 93.3% | |
| Mar 2026 | $464.45M | +92.8% | -6.1% | 14.6% | |
| Mar 2026 | $297.74M | +41.4% | -27.2% | 70.4% | |
| Sep 2026 | $296.3M | -12.4% | +10.4% | 10.2% | |
| Mar 2026 | $177.91M | +742.2% | +47.1% | 85.3% | |
| Mar 2026 | $155.66M | -43.4% | -9.5% | 35.1% | |
| Mar 2026 | $105.42M | +266.1% | +210.6% | 32.3% | |
| Mar 2026 | $76.44M | +12.7% | +26.0% | 22.8% | |
| Mar 2026 | $42.15M | -3.4% | -30.7% | 27.0% | |
| Peer median (excluding DYN) | $237.11M | +27.0% | +18.2% | 32.3% | |
Competitors are the stored peer set for DYN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 200.83M | 172.15M | 121.63M | 435.45M | 893.37M |
| Short-term Investments | 175.75M | 83.87M | 1.47M | 206.82M | 217.19M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 383K | 9.58M | 6.28M | 17.01M | 16.03M |
| Total Current Assets | 382.39M | 265.59M | 129.38M | 659.28M | 1.13B |
| Property, Plant & Equipment (Net) | 40.96M | 38.41M | 33.39M | 30.01M | 44.77M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 2.31M | 2.32M | 2.32M | 1.94M | 15.6M |
| Total Non-current Assets | 43.27M | 40.73M | 35.71M | 31.96M | 60.37M |
| Total Assets | 425.66M | 306.33M | 165.08M | 691.23M | 1.19B |
| Account Payables | 4.03M | 5.26M | 22.94M | 6.56M | 8.08M |
| Short-term Debt | 0 | 0 | 0 | 4.85M | 5M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 17.75M | 37.55M |
| Total Current Liabilities | 28.72M | 28.09M | 51.1M | 42.26M | 50.63M |
| Long-term Debt | 0 | 0 | 0 | 0 | 15.28M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 148.92M |
| Total Non-current Liabilities | 28.74M | 25.87M | 22.7M | 19.14M | 164.2M |
| Total Liabilities | 57.47M | 53.96M | 73.79M | 61.4M | 214.83M |
| Common Stock | 6K | 6K | 6K | 10K | 16K |
| Retained Earnings | (228.47M) | (396.57M) | (632.51M) | (949.93M) | (1.4B) |
| Accumulated OCI | (269K) | (571K) | 0 | 6K | 475K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 368.2M | 252.36M | 91.29M | 629.84M | 972.13M |
| Total Debt | 32.64M | 30.48M | 27.42M | 23.99M | 20.28M |
| Net Debt | (168.19M) | (141.66M) | (94.21M) | (411.46M) | (873.09M) |
Dyne Therapeutics, Inc.
NASDAQ:DYN
Intrinsic Alpha fair value
Locked
Current Price
$15.87
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.